RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona.
Bagai gives an overview of the lead candidate product RenovoGem that he has presented to the Congress, before going on to explain where the product is in its development cycle.
He says the product has met with "a lot of enthusiasm" so far and reveals his hopes of getting early approval from the FDA "next year or early in 2025."